Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
Date:8/5/2014

of a combination of deuterium modified dextromethorphan (an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter) and ultra-low dose quinidine (a CYP2D6 enzyme inhibitor). Incorporation of deuterium into specific positions of the dextromethorphan molecule strengthens the chemical bonds and reduces susceptibility to enzyme cleavage and first pass metabolism, but without altering its pharmacology. AVP-786 is an investigational drug not approved by the FDA.

About AVP-923AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter) plus low-dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. AVP-923 is being studied in several ongoing company sponsored Phase II clinical trials including agitation in Alzheimer's disease, levodopa-induced dyskinesia in Parkinson's disease, and multiple investigator initiated studies. AVP-923 is an investigational drug not approved by the FDA. AVP-923 at the 20/10 mg dose strength is approved by the FDA for the treatment of pseudobulbar affect (PBA) and marketed under the trade name NUEDEXTA (see description below). AVP-923 is an investigational drug not approved by the FDA for any uses other than PBA.

About NUEDEXTANUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

N
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Avanir Pharmaceuticals To Present at Three Conferences In May
2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)... 2014  ResMed (NYSE: RMD ), a pioneer ... to design complete sleep apnea solutions specifically for women, is ... of a good night,s sleep. The Better ... feeling tired is just part of living a busy life. ... critical pillar of health, essential to not only living an ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems (NYSE: ... report results for the fourth quarter of fiscal year ... October 22, 2014.  The news release will be followed ... 2:00 p.m. PT.  The news release and a link ... the company website at: www.varian.com/investor .  To access ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) ... -- may face an increased risk of dying in the next ... 3,000 older Americans, researchers found those who were unable to detect ... times as likely to die in the next five years, versus ... -- the inability to distinguish odors -- was a bigger predictor ...
(Date:10/2/2014)... scientists at The University of Nottingham could lead to ... , A drug resulting from the research, published in ... new hope to sufferers of chronic pain conditions such ... are currently available. , The work, led by Dr ... in collaboration with David Bates, Professor of Oncology in ...
(Date:10/1/2014)... that more than 80 per cent of bowel cancers ... found that medicines called ,JAK inhibitors, halted tumour growth ... present in more than 80 per cent of bowel ... in clinical trials, for diseases including rheumatoid arthritis, psoriasis, ... the second-most common cancer in Australia with nearly 17,000 ...
(Date:10/1/2014)... the Engineering and Physical Sciences Research Council (EPSRC) ... vital industrial control systems which run, for example, ... the rail network. , The research will ... malware infiltrating the systems behind our critical national ... Industrial Control Systems (RITICS), based at Imperial College ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... who cares for patients with cancer at The Children,s Hospital ... Junior Faculty Award in Pediatric Oncology. The American Society of ... award during its annual meeting, occurring June 1-5 in Chicago. ... B. Nachman, a pediatric oncologist and Professor of Pediatrics at ...
... TUESDAY, May 8 (HealthDay News) -- Eating too quickly may ... Researchers from Lithuania compared 234 people with type 2 ... those who gobble down their food were 2.5 times more ... while eating. Study participants with diabetes also were more ...
... Branch at Galveston researchers have discovered that a drug ... also have another important use: treating one of the ... rat and cell-culture experiments, the scientists found that metformin, ... in type 2 diabetes, also substantially reduced the effects ...
... physicians, fees under Medicare which in turn influence ... will pay doctors -- the Centers for Medicare and ... American Medical Association advisory panel. A study led by ... Public Health, found that the Medicare and Medicaid agency ...
... Reporter , MONDAY, May 7 (HealthDay News) -- Those suffering ... their symptoms, but a cure has yet to be found. ... may help patients suffer a little less, but side effects ... preparations impact symptoms of the common cold, there is currently ...
... -- The Medical Publishing Insights and Practices (MPIP) ... editors to characterize the persistent and perceived credibility ... potential approaches to resolve it. This unique round ... Recommendations for Closing the Credibility Gap in Reporting ...
Cached Medicine News:Health News:Diabetes drug could treat leading cause of blindness 2Health News:AMA committee recommendations on doctor fees set by Medicare are followed 9 times out of 10 2Health News:Zinc Pills May Shorten Colds, Analysis Suggests 2Health News:Journals and pharma collaborate on new recommendations 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: